72 results about "M2 phenotype" patented technology

The invention relates to a branched chain fatty acid composition and application thereof to regulation of brain nerve immunity, and belongs to the field of nutrient substance research. The present invention provides a branched chain fatty acid composition comprising C15: 0 and C17: 0. After the branched chain fatty acid composition is used for promoting LPS-induced microglial cells, the trend of promoting the microglial cells to be differentiated into M2 phenotype microglial cells is higher than the trend of promoting the microglial cells to be differentiated into M1 phenotype microglial cells, meanwhile, secretion of anti-inflammatory factors such as IL-4 and IL-10 is promoted, and secretion of proinflammatory factors such as NO, TNF-a and IL-1beta is inhibited. C15: 0 and C17: 0 in the branched chain fatty acid composition have a better synergistic effect and play a role in regulating brain nerve immunity.

The invention discloses a preparation method and application of a novel hybrid extracellular vesicle. According to the invention, vesicles derived from endothelial cells and neutrophil cells are combined with deferoxamine, and a biological mixed nano vesicle platform (DFO (HEVS)) is developed to solve the problem of diabetes wound healing. According to the dual-targeting system, DFO is accurately delivered to a wound part by utilizing CXCR4 mediated endothelial cell homing and beta2 integrin dependent inflammation tropism, DFO (at) HEVs activates and recovers vascular regeneration through HIF-1alpha / VEGF, ferroptosis is inhibited through Nrf2 / GPX4 signal transduction, macrophages are reprogrammed into a repair promoting M2 phenotype, and oxidative stress-inflammation-ferroptosis circulation is effectively broken.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to an inhalation type pharmaceutical composition for treating inflammatory respiratory diseases and a preparation method thereof. The inhalation type pharmaceutical composition comprises an active component and a nano-liposome, and mannose is modified on the surface of the nano-liposome; the active ingredients comprise bulbus fritillariae cirrhosae total alkaloids and platycodin D; the nano-liposome is prepared from the following raw materials: phospholipid, cholesterol and cholesterol-polyethylene glycol 1000-mannose ester. The liposome can be specifically recognized by a mannose receptor highly expressed on the surface of alveolar macrophage through a surface-modified mannose ligand, so that the receptor-mediated endocytosis is started, and the wrapped bulbus fritillariae cirrhosae total alkaloids and platycodin D are efficiently introduced into cells. The inhaled pharmaceutical composition of the present invention collectively pushes macrophages from a pro-inflammatory M1 phenotype to a repairable M2 phenotype. Therefore, the overall curative effect of the combination of the two components is far better than that of the independent use of any component.

The present invention relates to a branched fatty acid composition and its use in assisting the maintenance of nervous system health, and belongs to the field of nutrient research. The branched fatty acid composition provided by the present invention comprises C14:0, C15:0, C16:0 and C17:0. After LPS-induced microglia are treated with the branched fatty acid composition, the trend that the microglia can be promoted to differentiate into M2 phenotype microglia is higher than the trend that the microglia are promoted to differentiate into M1 phenotype microglia, while promoting the secretion of anti-inflammatory factors such as IL-4 and IL-10, and inhibiting the secretion of pro-inflammatory factors such as NO, TNF-a, and IL-1β. C14:0, C15:0, C16:0 and C17:0 in the branched fatty acid composition have a good synergistic effect, which plays a role in regulating brain immunity and maintaining the health of the central nervous system.

The invention is applicable to the field of new biomedical materials, and provides an antibacterial and immunoregulation hydrogel and a preparation method and application thereof, the hydrogel comprises oDex, EPL, TA and Fe < 3 + >, and three hydrogels with antibacterial, antioxidant, anti-inflammatory and immunoregulation functions can be obtained based on Schiff base bonds of oDex and EPL, ionic bonds and hydrogen bonds of TA and EPL and coordination of TA and Fe < 3 + >. The hydrogel has the advantages of being easy to operate, low in price and the like. The hydrogel has a photothermal therapy (PTT) combined EPL and TA / Fe < 3 + > compound sterilization function. The hydrogel has high adhesion, can effectively inhibit release of oxidative stress (RONS) and inflammatory factors by releasing TA, promotes polarization of macrophages from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, and can effectively promote healing of mouse diabetic bacterial infected wounds.

The invention provides in-situ forming fluid bionic hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides an injectable GelSSO / PDA (at) SDF fluid bionic niche, after in-situ photo-crosslinking, preferential and sustained release of PDA (at) SDF NPs initiates early signal amplification, which recruits EPCs and MSCs through an SDF-1 alpha / CXCR4 axis, promotes activation of the angiogenic vascular niche through an AKT signal, and repolarizes macrophages to a regenerated M2 phenotype. Subsequently, the gradual degradation of the bionic niche triggers the stable release of SSO, and the later signal is further amplified to form an osteogenic niche with transcriptional activity, thereby maintaining the MAPK / ERK-mediated MSCs osteogenic differentiation. The fluid bionic niche can form a niche conforming to defects through photopolymerization, the local immune imbalance and endogenous progenitor cell recruitment are corrected in the early stage, then formation of new vessels and lamellar bones is promoted, and finally vascularization regeneration of diabetic skull defects is achieved.

The invention discloses an acoustic catalyst as well as a preparation method and application thereof, and belongs to the technical field of catalysts and drug therapy. NJU-319 is selected as an acoustic catalyst, NJU-319Pt is synthesized from a porphyrinyl linker (TAPP) and a hexaphenyl triphenyl unit (HFPTP) under a solvothermal condition, and the H2 generation efficiency of NJU-319Pt can be further improved. After intraperitoneal injection, the nano-drug NJU-319Pt catalyzes H2O to be reduced into H2 under ultrasonic irradiation, and meanwhile lactic acid is oxidized into pyruvic acid. The action mechanism comprises: removing ROS and relieving oxidative stress; by inhibiting an NF-kappa B pathway, the transformation of macrophages from M1 phenotype to M2 phenotype is promoted, and inflammation is reduced; mitochondrial membrane potential is reduced, EMs cell apoptosis is induced, and focus growth is inhibited. The research provides a brand new EMs treatment strategy, combines acoustic catalysis H2 generation with lactic acid oxidation, and provides a new direction for EMs treatment research.

The invention provides a nano-micelle responding to an inflammation microenvironment as well as a preparation method and application of the nano-micelle. According to the nano-micelle, polyethylene glycol (PEG)-poly L-glutamic acid (PLG) is grafted with 4-hydroxymethyl phenylboronic acid (PBA), and the drug loading capacity of a hydrophobic anti-inflammatory drug is improved based on a hydrophobic effect and a borate bond formed by the PBA and a 1, 3-diol or 1, 2-diol structure of dexamethasone, curcumin and luteolin. The nano-micelle (PPDex micelle) has reversible splitting and rapid release behaviors under an inflammatory condition (the ROS level is increased or the pH value is reduced). The nano-micelle has a proper particle size, can effectively relieve inflammatory cell infiltration and pulmonary edema in the lung of an acute lung injury (ALI) mouse after pulmonary administration, reduces pro-inflammatory cytokines in the lung, inhibits oxidative stress, promotes polarization of macrophages from pro-inflammatory M1 phenotype to anti-inflammatory M2 phenotype, and finally inhibits the progress of ALI. The invention provides a novel effective anti-inflammatory strategy.

The invention relates to the technical field of medicines, in particular to application of a mesenchymal stem cell exosome in preparation of a thermoplegia neuroprotective agent. It is found through experiments that MSC-Exos can remarkably promote polarization conversion of microglial cells from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, and therefore damage, caused by heat stroke, to a central nervous system is relieved.

An in vivo and in vitro editing preparation method for CAR-MΦ targeting tumor stem cells, and a use thereof. The invention provides a chimeric antigen receptor-macrophage (CAR-MΦ) and a nano-carrier based on self-assembled nano-micelles, which can be applied to immunotherapy of glioma. According to the present invention, (PA)2 peptide nano-micelles loaded with CD133-CAR plasmids are constructed, and a citraconic anhydride-modified dextran, which is a group targeting macrophage specific target CD206, is adopted for modification. The carrier is used to realize CAR editing of macrophage in vivo and in vitro, so as to facilitate the re-education of tumor-related macrophage from an M2 phenotype to an M1 phenotype. At the same time, the surface markers of tumor stem cells are targeted to accurately target the tumor stem cells, phagocytize tumor cells, activate tumor immunity, remodel the tumor inhibition microenvironment and specifically kill brain glioma stem cells, thereby efficiently treating brain glioma.

The invention discloses nasal injection type baicalein hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving carboxymethyl chitosan in water, stirring to form a uniform carboxymethyl chitosan solution, then adding a 4-formylphenylboronic acid / baicalein solution, and then continuously stirring until yellow transparent hydrogel is formed, namely the nasal injection type baicalein hydrogel is obtained. The hydrogel has self-healing ability and proper viscosity, can be adhered to the epithelium of the nasal cavity and is continuously released in the microenvironment of the nasal cavity, so that the brain entering efficiency of the baicalein is remarkably improved; neurotoxic oligomers formed by abnormal aggregation of alpha-syn can be reduced; neuroinflammation can be relieved by regulating and controlling phenotypic polarization of microglial cells M2; oxidative stress can be improved by removing excessive ROS, dopaminergic neuron apoptosis is reduced, and the compound can be used for treating Parkinson's disease and has a good application prospect.

The invention relates to shape-specific cerium oxide nanoparticles (CNPs). methods of preparing CNPs. and methods of using CNPs to treat and / or inhibit and / or reduce and / or reverse the complications of respiratory syncytial virus (RSV) disease and other infections that cause pathologic immune responses. through the balance of favorable immunomodulation and reduced lung immunopathology. CNPs have the capability to switch between Ce3+ and Ce4+ oxidation states (e.g., to scavenge reactive oxygen species). The shape-specific CNPs are synthesized into various shapes and sizes. These properties offer an opportunity to utilize CNPs to modulate macrophage phenotypes along the spectrum of M1 and M2 phenotypes to combat RSV infection and other infections that cause pathologic immune responses.

The invention discloses bioactive glass composite hydrogel as well as a preparation method and application thereof. The bioactive glass composite hydrogel comprises a photo-crosslinking hydrogel matrix and magnesium-doped bioactive glass filled in the hydrogel, the photo-crosslinking hydrogel matrix is obtained by photo-curing and crosslinking methacrylic acid acylated protein; the magnesium-doped bioactive glass is a porous material. The magnesium-doped bioactive glass powder is doped into the hydrogel, so that the mechanical strength of the hydrogel can be remarkably enhanced, the bone repair activity of the hydrogel is remarkably improved compared with that of existing bioactive glass composite hydrogel, specifically, the expression of osteogenic differentiation related genes (BMP2, COL1, OPN and RUNX2) can be up-regulated, MPs can be induced to be polarized to M2 phenotype, the expression of M1 phenotype genes can be inhibited, and the bone repair activity of the hydrogel is remarkably improved. The polypeptide has excellent osteogenesis regulation and control performance and immune regulation capability.

The invention discloses an engineered exosome of LTH peptide modified miR-146a-5p and application, the core component of the medicine is the engineered exosome, and the engineered exosome is constructed by the following method: miR-146a-5p mimic infected human renal tubular epithelium HK2 cells with nucleotide sequences shown as SEQ ID NO.1-SEQ ID NO.2 are cultured and screened, the exosome rich in miR-146a-5p is separated from the culture supernatant of the cells, and the exosome rich in miR-146a-5p is obtained. Then, the kidney targeting peptide LTH is modified on the surface of the exosome. The invention reveals that HNRNP M protein is a key molecule for regulating and controlling miR-146a-5p to be sorted and enter the exosome for the first time, and verifies that the engineered exosome can be efficiently enriched in kidney, and by delivering miR-146a-5p to target IRAK1 gene in macrophage and inhibiting TRAF6 / IKK / NF-kappa B inflammation signal pathway, the macrophage is promoted to be polarized to a repairable M2 phenotype, so as to realize the purpose of improving the activity of the miR-146a-5p. And finally, the kidney injury induced by the calcium oxalate crystal is effectively relieved. The medicine has the advantages of clear mechanism, strong targeting property, good biocompatibility and the like, provides a brand new immunoregulation treatment strategy for renal injury, and has a wide clinical application prospect.

The invention belongs to the field of biological medicine, and particularly relates to a medicine for promoting microglial cell M2 type polarization and application of the medicine. The drug provided by the invention contains Densiflorol B. The drug provided by the invention has the advantages that the drug effect is good; the medicine can promote M2 type polarization of microglial cells, and has protection and repair effects on damaged nerves.

The invention belongs to the field of gene engineering, and particularly relates to a construction method of a gene engineering strain for producing glucosamine, a product and application. According to the method, intestinal probiotics with colonization ability are taken as an original strain, and multi-round CRISPR-Cas9 and Red homologous recombination technology combined transformation is carried out: on the basis of knockout of manX, ptsG is knocked out, a gna1 gene cluster derived from saccharomyces cerevisiae is inserted, then nagE is knocked out, and glmS driven by a strong promoter is inserted. In cell co-culture, the strain can safely and effectively promote phenotype transformation of a murine microglial cell line from BV2 to M2. In an animal model, the strain can colonize intestinal tracts in a short time and produce glucosamine, the effective concentration duration of glucosamine in serum is remarkably prolonged, inflammation is continuously inhibited, and the effect of enhancing immunity is achieved. And the strain does not have obvious toxicity, so that a new way is opened up for treating inflammatory diseases of engineering probiotics.

Compositions of matter and therapeutic methods for preventing, reducing, or reversing liver pathologies. Autologous pluripotent stem cells for generating monocytes or macrophages that are capable of suppressing liver failure. Methods of administering monocytes that are engineered or induced to facilitate hepatic regeneration. Hepatogenic cells such as monocytes are generated from induced pluripotent stem cells. Hepatogenic cells can be generated by overexpression of one or a plurality of factors associated with an M2 phenotype in pluripotent stem cell-derived monocytes such as signal transducer and activator of transcription 6 (STAT6) and transforming growth factor-beta. Hepatogenic monocytes can be generated in an environment that simulates liver injury.

The invention discloses a compound capable of treating skin wounds and a preparation method and application of the compound, relates to the field of skin wound healing, and aims to solve the problems that in the prior art, photo-thermal treatment cannot be compatible with sterilization and weak tissue damage, and sanshool is unstable and easy to degrade, the adopted technical scheme is that PCM is used for loading sanshool and TIIG NPs. Light energy can be converted into heat energy under the mild photo-thermal condition, then phase change of the phase change material lipidosome is promoted, sanshool is released, physical sterilization and chemical sterilization effects are achieved at the same time, the obvious antibacterial effect on staphylococcus aureus and escherichia coli in vitro is achieved, macrophages can be promoted to be polarized to anti-inflammatory M2 phenotype, and the anti-inflammatory effect of the phase change material lipidosome is improved. The wound surface inflammation reaction is relieved. And the compound can completely inhibit the growth of bacteria, promote collagen deposition and realize complete healing of infected wounds within 12 days. The compound has efficient antibacterial and tissue repair functions and is good in biocompatibility.

The invention provides application of microglial cell targeted IL-10mRNA (messenger Ribonucleic Acid) nano particles in preparation of a preparation or a composition or a medicine box for immunotherapy of cerebral arterial thrombosis. Specifically, the microglial cell targeting IL-10mRNA nanoparticle can specifically target M2 type microglial cells, so that IL-10mRNA is selectively delivered to the microglial cells at the cerebral arterial thrombosis occurrence part, and the microglial cells are driven to be polarized to M2 phenotype, thereby treating cerebral arterial thrombosis with blood-brain barrier injury.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic exosome derived from tumor cell membranes, its preparation method, and its applications. The preparation method of the biomimetic exosomes derived from tumor cell membranes provided by this invention includes the following steps: mixing LLC-derived cell membranes with doxorubicin and resveratrol solutions, and preparing biomimetic exosomes derived from tumor cell membranes by extrusion. The preparation method provided by this invention has advantages such as wide availability of raw materials, simple and controllable process, low technical threshold, and suitability for industrial-scale production. The biomimetic exosomes provided by this invention can effectively induce a specific immune response against tumor cells, achieving the purpose of inhibiting the progression of primary tumors and prolonging the survival of tumor-bearing mice. It can also promote the polarization of macrophages from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, laying a favorable foundation for the efficient implementation of subsequent immunotherapy and possessing broad application prospects.

The invention belongs to the technical field of biology, and particularly relates to application of SORBS2 in preparation of a medicine for treating melanoma. The technical problem to be solved by the invention is to provide a new choice for treating melanoma. The technical scheme of the invention is the application of SORBS2 protein in preparation of drugs for treating melanoma. The invention reveals that SORBS2 overexpression can inhibit growth and metastasis of melanoma, inhibit polarization of macrophages to M2 type and enhance anti-melanoma immune effect for the first time, and the SORBS2 overexpression can be used as a novel strategy for preparing and treating melanoma.

Methods according to certain embodiments include contacting a macrophage with a mannose receptor (CD206) binding agent in a manner sufficient to modulate activity of the macrophage. Methods for converting a phenotype of a macrophage from an M2 phenotype to an M1 phenotype are also provided. Methods for inhibiting growth of a CD206-expressing cell as well as methods for treating a subject for a neoplastic condition (e.g., cancer) or a condition associated with chronic inflammation are described. Immuno-modulating peptides suitable for use in the subject methods are also presented.

The invention discloses an M2 type microglial cell exosome and a preparation method and application thereof, and belongs to the technical field of biology, and the preparation method comprises the following steps: inoculating microglial cells at the density of 1 * 10 < 5 > cells / mL, treating the cells with IL-4 after the cells are adhered to the wall, inducing the cells to be polarized into an M2 phenotype, collecting a culture solution, and obtaining the M2 type microglial cell exosome M2-EXO through ultracentrifugation. After research, the M2-EXO is used for inhibiting neuroinflammation and improving sepsis-related encephalopathy of mice through miR-1949 mediated microglial cell phenotypic transformation. The research further finds that the M2-EXO can inhibit neuroinflammation through the miR-127-5p and improve the mouse schizophrenia caused by MK-801. Therefore, the invention also discloses an application of the M2-EXO and the miRNA thereof in treatment of sepsis-related encephalopathy and schizophrenia.

The present invention provides a polarity conversion promoter to anti-inflammatory M2 phenotype microglia. The polarity conversion promoter to anti-inflammatory M2 phenotype microglia comprises a cyclic peptide derivative represented by formula (1). In the formula, m=0-3, n≥1, R1-R6 are hydrogen atoms or hydrocarbon groups, R7 and R8 are carboxyl groups or salts thereof or alkoxycarbonyl groups, R9 is a hydrocarbon group, a hydroxyl group, an alkoxy group or an alkylcarbonyloxy group, and R 10 and R 11 is a hydrogen atom, a hydrocarbon group or an alkylcarbonyloxy group, R 12 ~R 16 It is a hydrogen atom or a hydrocarbon group. [Chemical formula 1] #imgabs0#

The application provides an amphiphilic functionalized D-form-alanine and a preparation method and application thereof, and a self-targeting carbon monoxide nanogenerator and a preparation method and application thereof, and belongs to the technical field of antibacterial materials. The application provides an amphiphilic functionalized D-form-alanine. The self-targeting carbon monoxide nanogenerator prepared by using the amphiphilic functionalized D-form-alanine changes the permeability of the outer membrane of the cell wall of gram-negative bacteria, is metabolically utilized by bacteria in a specific manner, generates CO under the action of light to kill bacteria, removes biofilms that are not easy to touch and are hidden in deep periodontal pockets, simultaneously relieves inflammation by inducing macrophages to polarize from an M1 phenotype to an M2 phenotype, further promotes alveolar bone regeneration, and avoids damage to normal tissues.

The present invention provides a polymer and a preparation method thereof, a hydrogel and a wound dressing. The polymer is formed by a Schiff base reaction between a block copolymer and a glycosaminoglycan aldehyde derivative. Among them, the block copolymer includes an end-aminated polyethylene glycol segment and a polyamino acid chain segment, and the polyamino acid chain segment includes a poly-L-methionine segment and a poly-L-ornithine segment. The hydrogel formed by the above polymer of the present invention has an immunomodulatory effect and can reduce the high reactive oxygen species level in the wound microenvironment. At the same time, the two components of the block copolymer and the glycosaminoglycan aldehyde derivative in the hydrogel can enhance the phagocytic function of macrophages and promote the transformation of macrophages into the M2 phenotype to regulate the wound microenvironment and achieve the purpose of promoting the healing of chronic wounds.

The present disclosure relates to compounds of Formula I, Formula II, and Formula III, and pharmaceutically acceptable salts thereof. Variables X, a, b, c, d, R 1‑4 , R 10‑15 and R 17‑22 are disclosed. These compounds can be used for treating cancer disorders, particularly those involving the M2 phenotype of macrophages. Pharmaceutical compositions comprising a compound of Formula I or Formula II or Formula III, and methods of treatment, which include administering compounds of Formula I, Formula II, and Formula III, are also disclosed.

The invention relates to the field of biological medicines, in particular to application of a reagent for inhibiting CYBB expression of tumor-associated macrophages in preparation of medicines for treating liver cancer and sensitizing a PD-1 inhibitor. The invention reveals that CYBB + TAMs can be used as a marker of poor curative effect of PD-1 on treating liver cancer for the first time. Targeted CYBB can activate a cGAS-STING pathway by reprogramming tumor-related macrophages from an M2 phenotype (tumor promotion) to an M1 phenotype (tumor resistance), and then improve the tumor killing function of CD8 + T cells, thereby inhibiting the growth of liver cancer and promoting the curative effect of a PD-1 inhibitor on liver cancer. By inhibiting the CYBB gene, the growth of the liver cancer can be inhibited, and the sensitivity of the liver cancer to a PD-1 inhibitor can be improved, so that the curative effect of immunotherapy is improved.

The technology described herein is directed to monospecific anti-LILRB2 antibody constructs, as well as bispecific anti-LILRB2 antibody constructs that also inhibit targets such as PD-1 or VEGF. Such antibody constructs are capable of polarizing macrophages from an M2 phenotype to an M1 phenotype, activating T cells, and / or inhibiting growth of a cancer. Also described herein are nucleic acids and vector encoding such monospecific or bispecific anti-LILRB2 antibody constructs, cells expressing or in combination with such antibody constructs, and compositions comprising such antibody constructs, nucleic acids, vectors, or cells. The disclosure also relates to methods of modulating the immune or treating cancer using such monospecific or bispecific anti-LILRB2 antibody constructs.

The present application relates to a DNA drug, a gene targeting delivery system and its application in the treatment of lower extremity peripheral arterial disease. Specifically, the present application relates to a microcrystalline nanocarbon targeted drug delivery system and a plasmid containing human interleukin-4 gene loaded thereon. The delivery system comprises a matrix microcrystalline nanocarbon, and folate, polyethyleneimine and polyethylene glycol modified on the surface thereof. The matrix microcrystalline nanocarbon has a size of 5-20 nanometers, a crystallinity of >80%, a rich mesoporous structure, a high specific surface area and good biocompatibility. The present application also provides a preparation method of the system, which comprises the steps of synthesizing a matrix by pulse modulation radio frequency plasma enhanced chemical vapor deposition, surface functionalization modification and plasmid loading. After injection into the lower extremity muscle, the system can actively target the macrophages in the ischemic site, realize long-term expression of the IL-4 gene at the lesion site. It can effectively promote stable, mature functional angiogenesis by inducing macrophages to polarize to the repair M2 phenotype and regulating the OSM / GSNOR / ENG signal axis, thereby improving limb ischemia. The present application has important application value in the field of gene therapy for ischemic diseases, especially peripheral arterial disease and severe limb ischemia.